研究单位：[1]Geneplus-Beijing Co. Ltd.[2]Cancer Hospital Chinese Academy of Medical Sciences Beijing,Beijing,China,100021[3]China-Japan Friendship Hospital Beijing,Beijing,China,100029[4]Beijing Friendship Hospital,Capital Medical University Beijing,Beijing,China,100050[5]Xuanwu Hospital Capital Medical University Beijing,Beijing,China,100053[6]Beijing Chest Hospital,Capital Medical University Beijing,Beijing,China,101149[7]Fourth Hospital of Hebei Medical University Shijiazhuang,Hebei,China,050011[8]Hebei General Hospital Shijiazhuang,Hebei,China,050051[9]Tangshan People's Hospital Tangshan,Hebei,China,063001[10]The First Bethune Hospital of Jilin University Changchun,Jilin,China,130021
研究目的：
Tumor genomic clonal evolution assessed with liquid biopsy of stage IB,II and IIIA non-small cell lung cancer patients after getting radical resection. Plasma circulating tumor DNA (ctDNA) analysis detects molecule residual disease and predicts recurrence in patients. The concordance of the relative abundance of mutations in plasma ctDNA with cancer recurrence.
